Regulatory news / Area HIV 20 maggio 2024 Spring European Testing Week: gli esperti dell’Iss, un test può fare la differenza per prendere di mira l’Hiv, l’Epatite C e la Sifilide
Prodotti competitors / Area Oncology 17 maggio 2024 FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
Prodotti competitors / Area Oncology 17 maggio 2024 Atezolizumab in early-relapsing mTNBC did not show a statistically significant improvement in PFS or OS
Regulatory news / Area Oncology 17 maggio 2024 Real world data analysis on ADC sequencing showed that time to next treatment is similar for the first and second ADC used, irrespective of HR-status. However, with limited data, no definitive conclusions can be drawn yet
Prodotti competitors / Area Liver 16 maggio 2024 FDA rejects label expansion for Dynavax’s hepatitis B vaccine
Prodotti competitors / Area Oncology 11 maggio 2024 EMA validates Opdivo+Yervoy combo's extension of indication in 1L mCRC
Prodotti competitors / Area Kite, Area Onco-Ema 11 maggio 2024 EMA granted a PRIME Designation to allogenic off-the shelf CAR-T (WU-CART-007) for the treatment of Relapsed/Refractory T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)
Prodotti competitors / Area Liver 11 maggio 2024 Zydus has announced the completion of enrollment of the pivotal Phase 2b/3 of saroglitazar in patients with PBC
Prodotti competitors / Area HIV 9 maggio 2024 MHRA approves cabotegravir - new medicine formulations for HIV prevention
